Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

After three years, 57% of patients taking Imfinzi were still alive, compared to 47% of the placebo group, making Imfinzi the first and only immunotherapy to show a survival benefit in LS-SCLC and ...

AstraZeneca is celebrating two new approvals for cancer therapies Imfinzi and Enhertu in the EU as it faces the threat of increased competition to its top seller Tagrisso. Daiichi Sankyo-partnered ...